As a biological antiviral agent, Interferon beta 1-a is now a leading candidate for the treatment of COVID-19 patients due to its beneficial effects seen in multiple reports and clinical trials.22,23 On the other hand, some reports have failed to show any association between Interferon use and improved clinical outcomes. The gene discussed is IFNB1; the disease is COVID-19.